Skip to main content

Advertisement

Figure 2 | BMC Psychiatry

Figure 2

From: Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study

Figure 2

During 8 weeks of quetiapine XR augmentation to antidepressant treatment among patients with a primary anxiety disorder or a mood disorder with comorbid anxiety symptoms, a statistically significant difference was observed between the quetiapine XR group and placebo group at Week 4 compared to baseline on the total HAM-A scores (p = 0.003).However, no statistically significant difference was observed between the two groups at Week 8 compared to baseline on the total HAM-A scores.HAM-A: Hamilton Anxiety Scale.

Back to article page